Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.78 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716677 | 1.00 | ADORA1 (0.85) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL3716662 | 0.94 | ADORA1 (0.86) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL32662178 | 0.93 | ADORA1 (0.85) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL32662091 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL32662392 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL32662022 | 0.92 | ADORA1 (0.84) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL120566 | 0.92 | ADORA1 (1.00) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL120567 | 0.92 | ADORA1 (1.00) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL14906549 | 0.87 | ADORA3 (1.00) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A | |
| SCHEMBL121829 | 0.86 | ADORA1 (0.86) | ADORA1ADORA3TAS1R3TAS1R1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | claimed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | claimed |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | claimed |
| WO-2016090005-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-06-09 | — | — | WO | claimed |
| EP-2968388-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | Inotek Pharmaceuticals Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| US-8877732-B2 | Combination, kit and method of reducing intraocular pressure | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-11-04 | — | — | US | claimed |
| WO-2014152733-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-18 | — | — | US | claimed |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | claimed |
| US-8470800-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-06-25 | — | — | US | claimed |
| US-8455457-B2 | Combination compositions for reducing intraocular pressure | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-06-04 | — | — | US | claimed |
| EP-2555776-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND NON-SELECTIVE BETA-ADRENERGIC RECEPTOR BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2013-02-13 | — | — | EP | claimed |
| EP-2555775-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2013-02-13 | — | — | EP | claimed |
| EP-2523669-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2012-11-21 | — | — | EP | claimed |
| WO-2010127210-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | WO | claimed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | disclosed |
| WO-2010127210-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA1 1957/4885ADORA3 3673/4885TAS1R3 4528/4885 |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | ADORA2A, ADORA1, PDE6C | ADORA1 2/4885ADORA3 4/4885TAS1R3 1163/4885 |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | ADORA1 2/4885ADORA3 7/4885TAS1R3 1118/4885 |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | ALDH1A2, GAP43, ALDH1A3 | ADORA1 101/4885ADORA3 226/4885TAS1R3 3391/4885 |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA1 1957/4885ADORA3 3673/4885TAS1R3 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.